ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) Share Price

Company Profile

Business description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Contact
1000 Zhangheng Road
Unit 15, China (Shanghai) Pilot Free Trade Zone
Pudong New Area
Shanghai
CHN
T: +86 2138016387
https://cn.immuneonco.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
202

Recommended

Investors are raising concerns about the future of telecommunication connectivity in Australia.

Brian Han | 17 June 2026

ASX top pick remains cheap as investor concerns around wage costs might be overdone.

Tyger Fitzpatrick | 17 June 2026

This ASX share remains overlooked despite a strong outlook.

Esther Holloway | 17 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,126.80	39.10	-0.43%
CAC 40	8,440.37	9.58	0.11%
DAX 40	25,003.75	69.08	0.28%
Dow JONES (US)	51,492.55	507.12	-0.98%
FTSE 100	10,448.01	60.60	-0.58%
HKSE	23,841.26	470.90	-1.94%
NASDAQ	26,021.66	354.69	-1.34%
Nikkei 225	71,053.49	1,151.24	1.65%
NZX 50 Index	13,363.31	29.67	-0.22%
S&P 500	7,420.10	91.25	-1.21%
S&P/ASX 200	8,911.10	37.60	-0.42%
SSE Composite Index	4,090.48	17.59	-0.43%